SCHEMBL25545533

SCHEMBL25545533

COCCOc1ccc(-c2nc(Cl)sc2C(C)C)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 5/20 0.36
S1PR4 O95977 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
DCK P27707 2/20 0.34
ALDH1A1 P00352 3/20 0.33
PTGS2 P35354 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPK1 P28482 1/20 0.33
PTGS1 P23219 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
PTGES O14684 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PI4KA P42356 1/20 0.33
PIK3CG P48736 1/20 0.33
PI4KB Q9UBF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545528 0.84 FBP1 (0.43) AAK1S1PR4DCKALDH1A1PTGS2
SCHEMBL25545564 0.83 S1PR4 (0.35) AAK1S1PR4ALDH1A1PTGS2SMN1; SMN2
SCHEMBL25545990 0.83 FBP1 (0.42) AAK1S1PR4DCKALDH1A1PTGS2
SCHEMBL25545547 0.83 AAK1 (0.36) AAK1S1PR4TRPV1DCKALDH1A1
SCHEMBL25545560 0.81 HTT (0.40) S1PR4DCKALDH1A1SMN1; SMN2KDM4E
SCHEMBL25545980 0.80 ALDH1A1 (0.36) AAK1S1PR4ALDH1A1PTGS2SMN1; SMN2
SCHEMBL25545524 0.80 NR1H4 (0.36) S1PR4ALDH1A1PTGS2SMN1; SMN2KDM4E
SCHEMBL25545551 0.79 FBP1 (0.43) AAK1S1PR4ALDH1A1PTGS2KDM4E
SCHEMBL25545968 0.78 CETP (0.38) PTGS2PTGS1TLR7
SCHEMBL25545536 0.78 TNK2 (0.36) S1PR4TLR7PIK3CAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 AAK1 1064/4885S1PR4 3887/4885TRPV1 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.